747 related articles for article (PubMed ID: 29289758)
1. Comparison of Autologous Stem Cell Transplantation versus Haploidentical Donor Stem Cell Transplantation for Favorable- and Intermediate-Risk Acute Myeloid Leukemia Patients in First Complete Remission.
Chen J; Yang L; Fan Y; Xu Y; Han Y; Tang X; Qiu H; Fu C; Miao M; Chen F; Wu D
Biol Blood Marrow Transplant; 2018 Apr; 24(4):779-788. PubMed ID: 29289758
[TBL] [Abstract][Full Text] [Related]
2. Comparable outcome after haploidentical and HLA-matched allogeneic stem cell transplantation for high-risk acute myeloid leukemia following sequential conditioning-a matched pair analysis.
Doppelhammer M; Fraccaroli A; Prevalsek D; Bücklein V; Häbe S; Schulz C; Hubmann M; Hausmann A; Claus R; Rank A; Schmid C; Tischer J
Ann Hematol; 2019 Mar; 98(3):753-762. PubMed ID: 30617644
[TBL] [Abstract][Full Text] [Related]
3. Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis.
Chang YJ; Wang Y; Liu YR; Xu LP; Zhang XH; Chen H; Chen YH; Wang FR; Han W; Sun YQ; Yan CH; Tang FF; Mo XD; Liu KY; Huang XJ
J Hematol Oncol; 2017 Jul; 10(1):134. PubMed ID: 28676064
[TBL] [Abstract][Full Text] [Related]
4. Combination of cytogenetic classification and MRD status correlates with outcome of autologous versus allogeneic stem cell transplantation in adults with primary acute myeloid leukemia in first remission.
Yao J; Zhang G; Liang C; Li G; Chen X; Ma Q; Zhai W; Yang D; He Y; Jiang E; Feng S; Han M
Leuk Res; 2017 Apr; 55():97-104. PubMed ID: 28189799
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the safety and efficacy of prophylactic donor lymphocyte infusion after haploidentical versus matched-sibling PBSCT in very high-risk acute myeloid leukemia.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2019 May; 98(5):1267-1277. PubMed ID: 30747249
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Salvatore D; Labopin M; Ruggeri A; Battipaglia G; Ghavamzadeh A; Ciceri F; Blaise D; Arcese W; Sociè G; Bourhis JH; Van Lint MT; Bruno B; Huynh A; Santarone S; Deconinck E; Mohty M; Nagler A
Haematologica; 2018 Aug; 103(8):1317-1328. PubMed ID: 29748438
[TBL] [Abstract][Full Text] [Related]
7. Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission.
Lorentino F; Labopin M; Bernardi M; Ciceri F; Socié G; Cornelissen JJ; Esteve J; Ruggeri A; Volin L; Yacoub-Agha I; Craddock C; Passweg J; Blaise D; Gedde-Dahl T; Poiani M; Fegueux N; Mohty M; Nagler A;
Am J Hematol; 2018 Oct; 93(10):1236-1244. PubMed ID: 30058714
[TBL] [Abstract][Full Text] [Related]
8. Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients.
Pagliardini T; Castagna L; Harbi S; Porta MD; Rey J; Fürst S; Bramanti S; Saillard C; Legrand F; Maisano V; Faucher C; Granata A; Hospital MA; Lining W; Weiller PJ; Calmels B; Charbonnier A; Lemarie C; Chabannon C; Vey N; Mokart D; Blaise D; Devillier R
Biol Blood Marrow Transplant; 2019 Sep; 25(9):1803-1809. PubMed ID: 31128325
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia.
Candoni A; De Marchi F; Zanini F; Zannier ME; Simeone E; Toffoletti E; Chiarvesio A; Cerno M; Filì C; Patriarca F; Fanin R
Exp Hematol; 2017 May; 49():25-33. PubMed ID: 28159598
[TBL] [Abstract][Full Text] [Related]
10. Myeloablative Haploidentical Transplantation Is Superior to Chemotherapy for Patients with Intermediate-risk Acute Myelogenous Leukemia in First Complete Remission.
Lv M; Wang Y; Chang YJ; Zhang XH; Xu LP; Jiang Q; Jiang H; Lu J; Chen H; Han W; Wang FR; Wang JZ; Chen Y; Yan CH; Zhang YY; Sun YQ; Mo XD; Zhu HH; Jia JS; Zhao T; Wang J; Liu KY; Huang XJ
Clin Cancer Res; 2019 Mar; 25(6):1737-1748. PubMed ID: 30478089
[TBL] [Abstract][Full Text] [Related]
11. Stem cell transplantation from a haploidentical donor versus a genoidentical sister for adult male patients with acute myelogenous leukemia in first remission: A retrospective study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation.
Gorin NC; Labopin M; Blaise D; de Groot M; Socié G; Bourhis JH; Ciceri F; Polge E; Nagler A; Mohty M
Cancer; 2020 Mar; 126(5):1004-1015. PubMed ID: 31774557
[TBL] [Abstract][Full Text] [Related]
12. Minimal residual disease status predicts outcome of acute myeloid leukaemia patients undergoing T-cell replete haploidentical transplantation. An analysis from the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT).
Canaani J; Labopin M; Huang XJ; Ciceri F; Van Lint MT; Bruno B; Santarone S; Diez-Martin JL; Blaise D; Chiusolo P; Wu D; Mohty M; Nagler A
Br J Haematol; 2018 Nov; 183(3):411-420. PubMed ID: 30117144
[TBL] [Abstract][Full Text] [Related]
13. T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Hodgkin Lymphoma Relapsed after Autologous Transplantation: Reduced Incidence of Relapse and of Chronic Graft-versus-Host Disease Compared with HLA-Identical Related Donors.
Mariotti J; Devillier R; Bramanti S; Sarina B; Furst S; Granata A; Faucher C; Harbi S; Morabito L; Chabannon C; Carlo-Stella C; Bouabdallah R; Santoro A; Blaise D; Castagna L
Biol Blood Marrow Transplant; 2018 Mar; 24(3):627-632. PubMed ID: 29197681
[TBL] [Abstract][Full Text] [Related]
14. Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT.
Piemontese S; Boumendil A; Labopin M; Schmid C; Ciceri F; Arcese W; Koc Y; Gulbas Z; Tischer J; Bruno B; Wu D; Blaise D; Beelen D; Irrera G; Ruggeri A; Houhou M; Mohty M; Nagler A;
J Hematol Oncol; 2019 Jul; 12(1):68. PubMed ID: 31272508
[TBL] [Abstract][Full Text] [Related]
15. Peritransplantation Glucocorticoid Haploidentical Stem Cell Transplantation Is a Promising Strategy for AML Patients With High Leukemic Burden: Comparison With Transplantations Using Other Donor Types.
Kaida K; Ikegame K; Inoue T; Maruyama S; Ishii S; Uchida N; Doki N; Eto T; Fukuda T; Katayama Y; Takada S; Kawakita T; Ichinohe T; Atsuta Y; Daimon T; Ogawa H
Transplant Cell Ther; 2023 Apr; 29(4):273.e1-273.e9. PubMed ID: 36641032
[TBL] [Abstract][Full Text] [Related]
16. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia.
Maurillo L; Buccisano F; Del Principe MI; Del Poeta G; Spagnoli A; Panetta P; Ammatuna E; Neri B; Ottaviani L; Sarlo C; Venditti D; Quaresima M; Cerretti R; Rizzo M; de Fabritiis P; Lo Coco F; Arcese W; Amadori S; Venditti A
J Clin Oncol; 2008 Oct; 26(30):4944-51. PubMed ID: 18606980
[TBL] [Abstract][Full Text] [Related]
17. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
[TBL] [Abstract][Full Text] [Related]
18. T-cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3-ITD in acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Canaani J; Labopin M; Huang XJ; Arcese W; Ciceri F; Blaise D; Irrera G; Corral LL; Bruno B; Santarone S; Van Lint MT; Vitek A; Esteve J; Mohty M; Nagler A
Am J Hematol; 2018 Jun; 93(6):736-744. PubMed ID: 29498106
[TBL] [Abstract][Full Text] [Related]
19. Comparable Outcomes After Alternative and Matched Sibling Donor Hematopoietic Stem Cell Transplantation and the Role of Molecular Measurable Residual Disease for Acute Myeloid Leukemia in Elderly Patients.
Cho BS; Yahng SA; Min GJ; Park S; Park SS; Shin SH; Jeon YW; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim M; Kim Y; Kim HJ
Transplant Cell Ther; 2021 Sep; 27(9):774.e1-774.e12. PubMed ID: 34082159
[TBL] [Abstract][Full Text] [Related]
20. Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and Outcomes.
Yu S; Fan Z; Ma L; Wang Y; Huang F; Zhang Q; Huang J; Wang S; Xu N; Xuan L; Xiong M; Han L; Sun Z; Zhang H; Liu H; Yu G; Shi P; Xu J; Wu M; Guo Z; Xiong Y; Duan C; Sun J; Liu Q; Zhang Y
JAMA Netw Open; 2021 Jul; 4(7):e2115991. PubMed ID: 34232303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
